SecBot SecBot

CTMX

CytomX Therapeutics, Inc.
Nasdaq· Pharmaceutical Preparations· Inc. DE· CIK 0001501989 Biotech & Drug Discovery
$1.99 −0.05 (−2.70%)
Nov 16 4:00 PM ET · prev $2.04
Market cap
$444.7M
Small cap
Consensus
Buy
93% Buy or better · 14 analysts
Median target
$12.00
+505% · range $5.00–16.00
1 year
−44.1%
from $3.55 · Nov 17
30 days
−15.2%
from $2.34
52-week range
$1.98–6.75
−71% from high · low Nov 9
Avg volume 20D
5.29M
Nov 10 spike 16.65M
Short interest
45.25M
≈20.8% of shares · +5.7%
Days to cover
12.0
at average volume
Insider net
−$1.2M
0 buyers · 4 sellers · 12 mo
New fund stakes
0
Q3 2026 13F · 0 exits
Filing reports
6
analyzed by SecBot
SecBot read BEARISH 5 reports · 90 days
Balance 1 bearish · 0 bullish · 1 mixed · 3 neutral oldest → newest, height = score
Avg score ·High conf. 4/5

Price

Daily candles with volume. Callouts mark insider and congressional trades, rating changes, 13F stakes, reports, catalysts, court and regulator actions, Reddit spikes and short-interest jumps. Hover one for the details (tap on phones).

Signal stack

Where each data set points today.

  • InsidersBEARISH

    4 insiders sold $1.2M.

  • InstitutionsBULLISH

    Q3 2026: 26 added (0 new), 7 trimmed or exited.

  • AnalystsBULLISH

    13 of 14 rate it Buy or better. Every target is above the price.

  • EstimatesRISING

    Current-quarter EPS estimate −$0.103 → −$0.082 over 90 days. 2 up, 0 down in 30 days.

  • Short sellersSTEADY

    Short interest +5.7% to 45.25M shares. 12.0 days to cover, ≈20.8% of shares.

  • TrendDOWNTREND

    22% below its 50-day average. New closing low $1.98 on Nov 10.

Who's buying

13F· Q3 2026
0
new positions
0
exits
FundMoveSharesValue
MARSHALL WACE, LLPADD4,362,687$11.9M
Qube Research & Technologies LtdDOUBLED4,187,989$11.4M
Squarepoint Ops LLCDOUBLED1,481,073$4.0M
Assenagon Asset Management S.A.DOUBLED1,181,259$3.2M
BNP PARIBAS FINANCIAL MARKETSDOUBLED825,279$2.2M
Jump Financial, LLCDOUBLED737,868$2.0M
DIMENSIONAL FUND ADVISORS LPTRIM639,545$1.7M
BARCLAYS PLCDOUBLED568,003$1.5M

Quarterly 13F filings are due 45 days after each quarter ends.

The Street

14 analysts
Buy 93% rate it Buy or better
Strong Buy6Buy7Hold1Sell0Strong Sell0
12-month targets · 8 analysts

Price is below the lowest target. Median implies +505%.Targets as of Nov 17, 2026.

Recent actions
DateFirmActionRating
Nov 12, 2026JP Morgan
MAINTAIN
MAINTAINOverweight
Nov 6, 2026Wedbush
MAINTAIN
MAINTAINOutperform
Aug 13, 2026JP Morgan
MAINTAIN
MAINTAINOverweight
Aug 10, 2026Guggenheim
MAINTAIN
MAINTAINBuy

Insider ledger

Form 4
$0
bought · 0 insiders
$1.2M
sold · 4 insiders
DateInsiderTypeValue
Aug 3, 2026
Carvajal Alejandra
Chief Legal Officer
Aug 3, 2026
AWARD450,000 sh
Aug 3, 2026
Carvajal Alejandra
Chief Legal Officer
Aug 3, 2026
AWARD100,000 sh
Jul 24, 2026
Fuchs Charles S.
Director
Jul 24, 2026
AWARD118,000 sh
Jun 17, 2026
Ashworth Alan
Director
Jun 17, 2026
AWARD59,000 sh
Jun 17, 2026
Mohindru Mani
Director
Jun 17, 2026
AWARD59,000 sh
Jun 17, 2026
Jones Elaine V
Director
Jun 17, 2026
AWARD59,000 sh
Jun 17, 2026
Su Zhen
Director
Jun 17, 2026
AWARD59,000 sh
Jun 17, 2026
Young Matthew P.
Director
Jun 17, 2026
AWARD59,000 sh

Earnings setup

Estimates
−$0.08
EPS estimate, this quarter
+20%
estimate change, 90 days
2↑ 0↓
revisions, 30 days
Current-quarter EPS estimate
PeriodEPS est.Range30D rev.Revenue
Current Q-$0.08-$0.11–-$0.05+20.3%$9.8M
Next Q-$0.10-$0.13–-$0.05+21.8%$5.1M
Current FY-$0.39-$0.51–-$0.33+0.7%$22.0M
Next FY-$0.50-$1.04–-$0.17-5.4%$26.1M

Short side

FINRA· Oct 30, 2026
45,246,966
shares short
+5.7%
vs prior settlement
12.0
days to cover
≈20.8%
of shares outstanding
Recent activity
The latest filings, insider trades, analyst actions, press and options flow, newest first.
Nov 10, 2026 SEC
State Street Corp filed a Schedule 13G disclosing a passive 4.1% stake in CytomX Therapeutics as of September 30…
SC 13G · Impact 2/10
Nov 5, 2026 SEC
CytomX reported Q3 2026 revenue of $1.7M, down from $6.0M a year ago due to the completion of the Astellas…
PRESS-RELEASE · Impact 5/10
Nov 5, 2026 Earnings
CytomX Therapeutics Announces Q3 2026 Financial Results and Provides Business Update
- Varsetatug masetecan (Varseta-M) granted FDA Fast Track designation for relapsed/refractory metast
Nov 5, 2026 SEC
Revenue decline reflects completion of the Astellas collaboration performance obligation. The company highlighted FDA…
8-K · Impact 4/10
Sep 30, 2026 Inst.
MARSHALL WACE, LLP · ADD
4,362,687 shares ($11.9M)
Sep 30, 2026 Inst.
Qube Research & Technologies · DOUBLED
4,187,989 shares ($11.4M)
Aug 3, 2026 Insider
Carvajal Alejandra was granted 450,000 shares
Chief Legal Officer
Aug 3, 2026 Insider
Carvajal Alejandra was granted 100,000 shares
Chief Legal Officer
Catalysts
Scheduled dates and disclosed events: earnings, FDA and trial readouts, halts, press releases. Colored dot = impact.
2 drugs tracked · Drug pipeline →
Recent
Nov 5, 2026
Earnings
CytomX Therapeutics Announces Q3 2026 Financial Results and Provides Business Update
- Varsetatug masetecan (Varseta-M) granted FDA Fast Track designation for relapsed/refractory metastatic colorectal cancer -
Nov 5, 2026
Earnings result
CTMX Q3 2026 Earnings: EPS $-0.09 (-1.5% vs est)
Oct 29, 2026
Earnings
CytomX Therapeutics to Report Third Quarter 2026 Financial Results on November 5, 2026
SOUTH SAN FRANCISCO, Calif., Oct. 29, 2026 (GLOBE NEWSWIRE) -- CytomX Therapeutics, Inc. (Nasdaq: CTMX), a leader in the field of masked…
Sep 1, 2026
Press release
CytomX Therapeutics to Present at Upcoming September Investor Conferences
SOUTH SAN FRANCISCO, Calif., Sept. 01, 2026 (GLOBE NEWSWIRE) -- CytomX Therapeutics, Inc. (Nasdaq: CTMX), a leader in the field of masked…
Aug 27, 2026
Press release
CytomX Therapeutics Announces FDA Fast Track Designation for Varsetatug masetecan (“Varseta-M”) for Relapsed/Refractory Metastatic Colorectal Cancer (R/R mCRC)
- Fast Track Designation follows encouraging Phase 1 data that were previously reported for R/R mCRC -

SecBot reports

6 filings · 4 press releases · 0 bullish · 1 bearish · 1 mixed · 4 neutral
All CTMX filing & press-release reports (10)